Photobiomodulation induces murine macrophages polarization toward M2 phenotype

Reis, Valdison Pereira dos; Paloschi, Mauro Valentino; Rego, Cristina Matiele Alves; Tavares, Maria Naiara Macedo; Boeno, Charles Nunes; Lopes, Jéssica Amaral; Ferreira, Alex Augusto Ferreira e; Soares, Andreimar Martins; Zamunér, Stella Regina; Zuliani, Juliana Pavan

doi:10.1016/j.toxicon.2021.05.009

Cited by 11 publications

(9 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PBM (945 nm, 3 J/cm 2 ) significantly reduced the gene expressions of IL-6 and TNF-α in isolated macrophages incubated with Bothrops jararacussu venom (BjV). Furthermore, this study indicated that PBM increased the polarization of macrophages to the M2 phenotype, repairing tissue and suppressing inflammation [ 102 ]. Liao et al also reported that PBM inhibited the inflammatory response through the macrophage M2 polarization in human THP-1 monocyte cells, human primary macrophages, and mice intraperitoneal macrophages, which was regulated by mitochondrial respiratory gene citrate synthase [ 103 ].…”

Section: Pbm Overviewmentioning

confidence: 99%

Therapeutic Potential of Photobiomodulation for Chronic Kidney Disease

Bean

Liebert

Bicknell

et al. 2022

IJMS

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a growing global public health problem. The implementation of evidence-based clinical practices only defers the development of kidney failure. Death, transplantation, or dialysis are the consequences of kidney failure, resulting in a significant burden on the health system. Hence, innovative therapeutic strategies are urgently needed due to the limitations of current interventions. Photobiomodulation (PBM), a form of non-thermal light therapy, effectively mitigates mitochondrial dysfunction, reactive oxidative stress, inflammation, and gut microbiota dysbiosis, all of which are inherent in CKD. Preliminary studies suggest the benefits of PBM in multiple diseases, including CKD. Hence, this review will provide a concise summary of the underlying action mechanisms of PBM and its potential therapeutic effects on CKD. Based on the findings, PBM may represent a novel, non-invasive and non-pharmacological therapy for CKD, although more studies are necessary before PBM can be widely recommended.

show abstract

Section: Pbm Overviewmentioning

confidence: 99%

Therapeutic Potential of Photobiomodulation for Chronic Kidney Disease

Bean

Liebert

Bicknell

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…LED (Light Emitting Diode) Treatment. Cells were irradiated with a 945 nm infrared LED device (model Super Bright LEDs, Inc., St. Louis, MO, USA) immediately upon addition of the venom or toxin in the culture and LED was applied with direct contact to the bottom of the well plate in a continuous mode for 30 s [14][15][16]. The experiments were conducted in an environment with partial obscurity to not suffer interference from external light.…”

Section: Endotoxin Quantificationmentioning

confidence: 99%

“…The output power of the LED equipment was measured using the Laser Check power meter (MM Optics, São Carlos, Brazil). The LED parameters, low enough to avoid any thermal effect, were chosen based on previous studies [11,[14][15][16]. The experimental parameters for the LED are presented in Table 1.…”

Section: Endotoxin Quantificationmentioning

confidence: 99%

“…Pereira dos Reis et al [14], Reis et al [15], and Reis et al [16] showed that LED photobiomodulation also has beneficial properties in vitro. When the phototherapy was applied to the elicited macrophages under snake venom or toxins effects, they were protected from death.…”

Section: Introductionmentioning

confidence: 99%

“…sisted of more than 95% TG-macrophages, as determined by morphological criteria[15,16,[18][19][20].2.7. Superoxide Dismutase (SOD), Catalase, and Peroxidase Enzymes Determinations.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Light Emitting Diode Photobiomodulation Enhances Oxidative Redox Capacity in Murine Macrophages Stimulated with Bothrops jararacussu Venom and Isolated PLA2s

Reis

Setúbal

Ferreira

et al. 2022

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Photobiomodulation therapy associated with conventional antivenom treatment has been shown to be effective in reducing the local effects caused by bothropic venoms in preclinical studies. In this study, we analyzed the influence of photobiomodulation using light emitting diode (LED) on the oxidative stress produced by murine macrophages stimulated with Bothrops jararacussu venom and it isolated toxins BthTX-I and BthTX-II. Under LED treatment, we evaluated the activity of the antioxidant enzymes catalase, superoxide dismutase, and peroxidase as well as the release of hydrogen peroxide and the enzyme lactate dehydrogenase. To investigate whether NADPH oxidase complex activation and mitochondrial pathways could contribute to hydrogen peroxide production by macrophages, we tested the effect of two selective inhibitors, apocynin and CCCP3, respectively. Our results showed that LED therapy was able to decrease the production of hydrogen peroxide and the liberation of lactate dehydrogenase, indicating less cell damage. In addition, the antioxidant enzymes catalase, superoxide dismutase, and peroxidase increased in response to LED treatment. The effect of LED treatment on macrophages was inhibited by CCCP3, but not by apocynin. These findings show that LED photobiomodulation treatment protects macrophages, at least in part, by reducing oxidative stress caused B. jararacussu venom and toxins.

show abstract

Photobiomodulation Therapy to Treat Snakebites Caused by Bothrops atrox

Carvalho,

Souza,

Melo

et al. 2024

JAMA Intern Med

View full text Add to dashboard Cite

ImportanceBothrops venom acts almost immediately at the bite site and causes tissue damage.ObjectiveTo investigate the feasibility and explore the safety and efficacy of low-level laser therapy (LLLT) in reducing the local manifestations of B atrox envenomations.Design, Setting, and ParticipantsThis was a double-blind randomized clinical trial conducted at Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, in Manaus, Brazil. A total of 60 adult participants were included from November 2020 to March 2022, with 30 in each group. Baseline characteristics on admission were similarly distributed between groups. Data analysis was performed from August to December 2022.InterventionThe intervention group received LLLT combined with regular antivenom treatment. The laser used was a gallium arsenide laser with 4 infrared laser emitters and 4 red laser emitters, 4 J/cm2 for 40 seconds at each application point.Main Outcomes and MeasuresFeasibility was assessed by eligibility, recruitment, and retention rates; protocol fidelity; and patients’ acceptability. The primary efficacy outcome of this study was myolysis estimated by the value of creatine kinase (U/L) on the third day of follow-up. Secondary efficacy outcomes were (1) pain intensity, (2) circumference measurement ratio, (3) extent of edema, (4) difference between the bite site temperature and that of the contralateral limb, (5) need for the use of analgesics, (6) frequency of secondary infections, and (7) necrosis. These outcomes were measured 48 hours after admission. Disability assessment was carried out from 4 to 6 months after patients’ discharge. P values for outcomes were adjusted with Bonferroni correction.ResultsA total of 60 patients (mean [SD] age, 43.2 [15.3] years; 8 female individuals [13%] and 52 male individuals [87%]) were included. The study was feasible, and patient retention and acceptability were high. Creatine kinase was significantly lower in the LLLT group (mean [SD], 163.7 [160.0] U/L) 48 hours after admission in relation to the comparator (412.4 [441.3] U/L) (P = .03). Mean (SD) pain intensity (2.9 [2.7] vs 5.0 [2.4]; P = .004), circumference measurement ratio (6.6% [6.6%] vs 17.1% [11.6%]; P &lt; .001), and edema extent (25.8 [15.0] vs 40.1 [22.7] cm; P = .002) were significantly lower in the LLLT group in relation to the comparator. No difference was observed between the groups regarding the mean difference between the bite site temperature and the contralateral limb. Secondary infections, necrosis, disability outcomes, and the frequency of need for analgesics were similar in both groups. No adverse event was observed.Conclusions and RelevanceThe data from this randomized clinical trial suggest that the use of LLLT was feasible and safe in a hospital setting and effective in reducing muscle damage and the local inflammatory process caused by B atrox envenomations.Trial RegistrationBrazilian Registry of Clinical Trials Identifier: RBR-4qw4vf

show abstract

Photobiomodulation induces murine macrophages polarization toward M2 phenotype

Cited by 11 publications

References 23 publications

Therapeutic Potential of Photobiomodulation for Chronic Kidney Disease

Therapeutic Potential of Photobiomodulation for Chronic Kidney Disease

Light Emitting Diode Photobiomodulation Enhances Oxidative Redox Capacity in Murine Macrophages Stimulated with Bothrops jararacussu Venom and Isolated PLA2s

Photobiomodulation Therapy to Treat Snakebites Caused by Bothrops atrox

Contact Info

Product

Resources

About